<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064634</url>
  </required_header>
  <id_info>
    <org_study_id>GCSB_OS</org_study_id>
    <nct_id>NCT02064634</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule</brief_title>
  <official_title>A Multicenter, Comparative, Open Label, Prospective Observational Study on Discontinuation of Medication Due to Gastrointestinal Adverse Effects for the Patients Being Treated for Osteoarthritis With Anti-inflammatory Analgesic Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates how gastrointestinal toxicity affects discontinuation of medication
      given to patients with osteoarthritis in routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discontinuation rate due to gastrointestinal adverse effects</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of medication discontinuation recorded as lack of efficacy</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Number of participants discontinued from medication due to lack of efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of medication discontinuation</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Number of participants discontinued from medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate due to adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">6700</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Shinbaro (only)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib (only)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Shinbaro + NSAIDs</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Shinbaro + Celecoxib</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with osteoarthritis being treated with anti-inflammatory analgesic drug at general
        hospitals and clinics in South Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum 20- year-old patients diagnosed with osteoarthritis

          -  Within 2 weeks prior to participation, not taken anti-inflammatory analgesic drug such
             as the Shinbaro Capsule, Celecoxib Capsule and NSAIDs(non-steroidal anti-inflammatory
             drugs)

          -  Written consent form voluntarity

        Exclusion Criteria:

          -  Diagnosed with disease that may affect measurement of efficacy clinically

          -  Diagnosed with clinically significant phycological disorder, and taking medication

          -  Participated in a clinical trial within 4 weeks

          -  Pregnant or lactating woman

          -  History of malignant disease within the previous 5 years

          -  Patients who seem not to participate in the study at investigator's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seong-Il Bin, M.D., Ph.D</last_name>
    <phone>82-2-3010-3530</phone>
    <email>sibin@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Sonpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Il Bin, M.D., Ph.D</last_name>
      <phone>82-2-3010-3530</phone>
      <email>sibin@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shinbaro Capsule</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>GCSB-5</keyword>
  <keyword>Discontinuation rate</keyword>
  <keyword>Gastrointestinal adverse event</keyword>
  <keyword>NSAIDs</keyword>
  <keyword>OASIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

